Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Dacarbazine in BRAF+ Melanoma
NCT00936221Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of selumetinib in melanoma, sponsored by AstraZeneca. Started Jul 2009; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00936221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936221.